Corvex R&D increased by 4.1% to $822.00K in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 65.2%, from $2.36M to $822.00K. Over 3 years (FY 2021 to FY 2025), R&D shows a downward trend with a -24.8% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.36M | $3.36M | $3.36M | $4.59M | $4.11M | $3.89M | $4.17M | $5.64M | $3.19M | $2.89M | $2.91M | $3.40M | $2.00M | $2.36M | $1.40M | $1.17M | $790.00K | $822.00K |
| QoQ Change | — | +0.0% | +0.0% | +36.8% | -10.4% | -5.3% | +7.1% | +35.1% | -43.4% | -9.6% | +0.7% | +17.1% | -41.3% | +18.4% | -40.7% | -16.8% | -32.2% | +4.1% |
| YoY Change | — | — | — | — | +22.5% | -15.2% | +1.4% | — | — | -25.9% | -30.3% | -39.6% | -37.4% | -18.1% | -51.8% | -65.7% | -60.4% | -65.2% |
| Segment | Q1 '24 | Q1 '25 |
|---|---|---|
| Chief Operating Decision Maker | $2.70M | $2.29M |
| Total | $2.89M | $2.36M |
Chief Operating Decision Maker was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.